

Five action points for a HAEppier tomorrow




More information?
Check our **White Paper**⁴

Approach


The **2021 update** of the **WAO/EAACI guideline** states that the treatment goal for HAE patients is **total disease control** and a **normal life**. It also introduces **new innovative long-term prophylactic therapies** as first-line treatment options.¹

In **June 2022**, a **panel of Belgian HAE experts** reviewed the Belgian situation, based on a patient registry² and expert opinion analysis,³ in light of the updated guideline.



Key findings

Impact on daily living, in % of patients, according to experts³




The swellings can be very **painful** and can occur in **different locations**, resulting in **difficulties performing daily tasks** at work/school/hobbies and a **constant fear** for the next attack.



Of those treated with a long-term prophylactic, only **3 of out 5** are treated with first-choice recommended therapies.

Treatment landscape before July 2022³



Five **action points** for Belgium were formulated to align with the updated guideline:⁴

- 1 **Work towards total disease control and normalize patients' life by considering the use of new and innovative long-term prophylactic treatment options.**
- 2 **Inform HAE patients about new long-term prophylactic therapy available in Belgium**
- 3 **Assure the availability of on-demand therapy for all C1-INH HAE patients**
- 4 **Implement a more formal assessment including multiple aspects of the disease in the daily clinical practice**
- 5 **Continue and expand the existing patient registry to assure continued data availability on HAE in Belgium**